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TDP-43 mediates degeneration in a novel Drosophila model of
disease caused by mutations in VCP/p97
Abstract
Inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia
(IBMPFD) is a dominantly inherited degenerative disorder caused by mutations in the
valosin-containing protein (VCP7) gene. VCP (p97 in mouse, TER94 in Drosophila melanogaster, and
CDC48 in Saccharomyces cerevisiae) is a highly conserved AAA(+) (ATPases associated with multiple
cellular activities) ATPase that regulates a wide array of cellular processes. The mechanism of IBMPFD
pathogenesis is unknown. To elucidate the pathogenic mechanism, we developed and characterized a
Drosophila model of IBMPFD (mutant-VCP-related degeneration). Based on genetic screening of this
model, we identified three RNA-binding proteins that dominantly suppressed degeneration; one of these
was TBPH, the Drosophila homolog of TAR (trans-activating response region) DNA-binding protein 43
(TDP-43). Here we demonstrate that VCP and TDP-43 interact genetically and that disease-causing
mutations in VCP lead to redistribution of TDP-43 to the cytoplasm in vitro and in vivo, replicating the
major pathology observed in IBMPFD and other TDP-43 proteinopathies. We also demonstrate that
TDP-43 redistribution from the nucleus to the cytoplasm is sufficient to induce cytotoxicity.
Furthermore, we determined that a pathogenic mutation in TDP-43 promotes redistribution to the
cytoplasm and enhances the genetic interaction with VCP. Together, our results show that degeneration
associated with VCP mutations is mediated in part by toxic gain of function of TDP-43 in the
cytoplasm. We suggest that these findings are likely relevant to the pathogenic mechanism of a broad
array of TDP-43 proteinopathies, including frontotemporal lobar degeneration and amyotrophic lateral
sclerosis.
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Abstract
Inclusion body myopathy associated with Paget’s disease of bone and frontotemporal dementia
(IBMPFD) is a dominantly inherited degenerative disorder caused by mutations in the valosin-
containing protein (VCP) gene. VCP (p97 in mouse, TER94 in D. melanogaster, and CDC48 in S.
cerevisiae) is a highly conserved AAA+-ATPase that regulates a wide array of cellular processes.
The mechanism of IBMPFD pathogenesis is unknown. To elucidate the pathogenic mechanism, we
developed and characterized a Drosophila model of IBMPFD (mutant VCP–related degeneration).
Based on genetic screening of this model we identified three RNA-binding proteins that dominantly
suppressed degeneration; one of these was TBPH, the Drosophila homolog of TAR DNA-binding
protein (TDP-43). Here we demonstrate that VCP and TDP-43 interact genetically and that disease-
causing mutations in VCP lead to redistribution of TDP-43 to the cytoplasm in vitro and in vivo,
replicating the major pathology observed in IBMPFD and other TDP-43 proteinopathies. We also
demonstrate that TDP-43 redistribution from the nucleus to the cytoplasm is sufficient to induce
cytotoxicity. Furthermore, we determined that a pathogenic mutation in TDP-43 promotes
redistribution to the cytoplasm and enhances the genetic interaction with VCP. Taken together, our
results show that degeneration associated with VCP mutations is mediated in part by toxic gain-of-
function of TDP-43 in the cytoplasm. We suggest that these findings are likely relevant to the
pathogenic mechanism of a broad array of TDP-43 proteinopathies, including frontotemporal lobar
degeneration and amyotrophic lateral sclerosis.
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INTRODUCTION
Inclusion body myopathy associated with Paget’s disease of bone and frontotemporal dementia
(IBMPFD; MIM167320) is a rare, complex and ultimately lethal autosomal dominant disorder.
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Affected individuals exhibit variable penetrance of progressive degeneration of muscle, bone
and brain caused by mutations in the gene encoding valosin-containing protein (VCP) (Watts
et al., 2004) (Kimonis et al., 2008). The molecular chaperone VCP (also known as p97, TER94,
and CDC48) is a member of the AAA+ family of proteins (ATPases associated with multiple
cellular activities) that segregates ubiquitinated substrates from multimeric protein complexes
or structures (Ye, 2006). VCP activity is essential for multiple cellular processes, including
ubiquitin-dependent protein degradation, nuclear envelope construction, Golgi and
endoplasmic reticulum assembly, and autophagosome maturation (Halawani and Latterich,
2006; Ju et al., 2009; Tresse et al., 2010). The molecular basis of degeneration resulting from
VCP mutations is unknown, although ubiquitin-positive pathology is prominent in affected
tissues (Guinto et al., 2007; Weihl et al., 2008). TAR DNA-binding protein 43 (TDP-43) has
been identified as a major component of the ubiquitin pathology (Neumann et al., 2007;
Salajegheh et al., 2009).
TDP-43 is a predominantly nuclear hnRNP that undergoes nucleocytoplasmic shuttling and
associates with translation machinery in the cytoplasm (Ayala et al., 2008; Wang et al.,
2008; Freibaum et al., 2009). TDP-43 is redistributed to the cytoplasm after neuronal injury
where it associates with stress granules (Colombrita et al., 2009; Moisse et al., 2009a). TDP-43
redistribution to the cytoplasm is recognized as a pathological feature of several sporadic and
inherited human diseases including IBMPFD, frontotemporal dementia and amyotrophic
lateral sclerosis, although the significance of this is unclear (Neumann et al., 2007; Geser et
al., 2009; Salajegheh et al., 2009). TDP-43 redistribution has also been observed in vitro in
cells expressing mutant VCP, although the role of TDP-43 in mediating disease has not been
explored (Gitcho et al., 2009). The recent identification of disease-associated mutations in
TDP-43 strongly implicate this protein in disease pathogenesis (Gitcho et al., 2008; Kabashi
et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki
et al., 2008), although it is not known whether disease-associated cytoplasmic accumulation
of TDP-43 is a mediator of pathology or a physiological response to it.
Here we present the first Drosophila melanogaster model of IBMPFD. Through genetic
screening we identified three RNA-binding proteins that suppress degeneration. One of these
was TBPH, the fly orthologue of TDP-43. We show in vitro that expression of disease-causing
VCP mutants leads to cytotoxicity and coincidental redistribution of TDP-43. To determine
the significance of TDP-43 redistribution, we generated transgenic flies expressing wild type
(WT) and mutant forms of TDP-43. We demonstrate that VCP and TDP-43 interact genetically,
that disease-causing mutations in VCP lead to redistribution of TDP-43 to the cytoplasm in
vivo, and that redistribution of TDP-43 is sufficient to induce degeneration in vivo. Thus, our
study provides the first evidence that toxic gain-of-function of TDP-43 in the cytoplasm plays
a primary role in mediating the pathogenesis initiated by mutations in VCP.
MATERIALS AND METHODS
Plasmids
To generate pUAST-dVCP constructs, dVCP cDNA in the pBluescript SK–(pBS sequence
variants were generated using Stratagene’s QuikChange SDM Kit (Agilent Technologies,
Cedar Creek, CA), changing R to H at amino acid (aa) 152 (R152H), A to E at aa 229 (A229E)
and subsequently subcloned into pUAST. To generate DsRed VCP, VCP cDNA was obtained
from Origene and sequence variants R95G, R155H, R155C, R191Q and A232E were generated
using Stratagene’s QuikChange SDM kit. Wild type and mutant VCP were then subcloned into
the BglII/BamH1 cloning site of pDsRed Monomer-C1 vector (Clontech). TBPH cDNA was
obtained from Origene and subcloned into the EcoRI/XhoI site of pUAST. WT, NLS- and
NES-mutant TDP-43 cDNAs were amplified from the previously described mammalian
expression constructs (Winton et al., 2008). Using the Stratagene’s QuikChange SDM kit,
Ritson et al. Page 2
J Neurosci. Author manuscript; available in PMC 2010 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
TDP-43 M337V (M to V at aa337) was generated from WT TDP-43. All TDP-43 constructs
were subcloned into the NotI/XhoI cloning site of pUAST.
Fly culture
All Drosophila stocks were maintained on standard media in 25°C incubators. Double-strand
RNAi lines targeting TBPH (ID38377), xl6 (ID31202, ID31203) and Hrb27C (ID16040,
16041) were obtained from the Vienna Drosophila RNAi Center. Flies transgenic for UAS-
dVCP (WT or mutant), UAS-TBPH and UAS-TDP-43 (WT or mutant) were generated by
injecting the constructs described above into embryos of w1118 using standard techniques.
Dominant modifier screen
Deficiency (Df) lines for all four chromosomes obtained from the Bloomington stock center
were used to identify dominant modifiers of mutant dVCP in a genetic screen. For the primary
screen, balanced virgin female dVCP R152H (recombined with Gmr GAL4) flies were crossed
with Df/Balancer males from 270 deficiency lines and progeny were examined for changes in
eye phenotype (including color, ommatidia structure and bristle formation). At least ten
progeny were examined and scored on a twenty-point scale. Eyes were examined for the
presence of: supernumerary inter-ommatidial bristles (IOBs), IOBs with abnormal orientation,
necrotic patches, a decrease in size, retinal collapse, fusion of ommatidia, disorganization of
ommatidial array and loss of pigmentation. Points were added if: there was complete loss of
IOBs (+1), more than 3 small or 1 large necrotic patch (+1), retinal collapse extended to the
midline of the eye (+1) or beyond (+2), loss of ommatidial structure in less than 50% (+1) or
more than 50% (+2) of the eye, and if pigmentation loss resulted in change of eye color from
red to orange (+1) or pale orange/white (+2). Gmr, GAL4, UAS dVCP R152H / Balancer served
as an internal control. In a secondary screen to filter nonspecific modifiers of cell death,
deficiencies defined as hits (either enhancing or suppressing the dVCP mutant phenotype) were
then crossed with flies expressing the pro-apoptotic gene Reaper (recombined with Gmr
GAL4). Any hits that similarly affected dVCP R152H and Reaper in the secondary screen were
excluded from further study due to the possibility of non–specific anti-apoptotic effects. As
regions of interest were identified from the primary and secondary screens, additional Df lines
were obtained that overlapped with interacting deficiencies to verify and refine the position of
potential modifiers. For the final step of gene identification, individual RNAi lines
corresponding to the genes within the candidate intervals were obtained from the Vienna
Drosophila RNAi Center. Gmr GAL4, UAS dVCP R152H females were crossed with males
from the RNAi lines and the progeny eyes were evaluated for changes. A modifier was defined
as an RNAi line that replicated the enhancement or suppression of the corresponding
deficiency.
Cell culture and transfection
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% L-glutamate. HEK293T
cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Primary cortical neurons were cultured from postnatal day zero C57Bl/6J pups.
Briefly, pups were decapitated into Hanks medium without Ca2+ and Mg2+, and cortices were
dissected in Neurobasal-A medium supplemented with 10 mM HEPES. After dissection,
cortices were trypsinized for 25 minutes at 37°C and dissociated. Neurons were plated in
Neurobasal-A with B27 supplement at a density of 2.5 × 105 cells per well in 4-well chamber
CC2 slides (Nalge-Nunc). After 4 days in vitro (DIV), cells were transfected with 1ug plasmid
DNA using Lipofectamine 2000 (Invitrogen) as suggested by the manufacturer.
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Immunoblots
To examine soluble and insoluble fractions of TDP-43 in cells, HEK293T cells were harvested
at the indicated times and RIPA-soluble and insoluble fractions were prepared as previously
described (Winton et al., 2008). To examine proteins expressed in flies, 3 fly heads (or thoraces)
of the appropriate genotype were lysed in 20 μL of RIPA. For immunoblots (IB), 20 μg of cell
lysates or lysate from 3 fly head equivalents were resolved on 10% SDS-PAGE and transferred
to a nitrocellulose membrane (BioRad), and IB was performed as described (Pandey et al.,
2007). Mouse monoclonal anti-VCP antibody (Affinity BioReagent) was used at 1:10000;
rabbit polyclonal anti-TDP-43 antibody raised against recombinant TDP-43 (Protein Tech
Group) at 1:1000; mouse monoclonal anti-tubulin (Sigma) at 1:10000; and rabbit polyclonal
anti-actin (Santa Cruz) at 1:3000. Primary antibodies were detected with horseradish
peroxidase–conjugated anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch) and proteins
were visualized using Immobilon Western Chemiluminescent AP Substrate (Millipore).
Real-time quantitative PCR
Total RNA was isolated from 10 animals of the appropriate genotype with TRIzol reagent
(Invitrogen) and cDNA was generated using the iScript cDNA Synthesis kit (BioRad)
following the manufacturer’s protocol. The concentration of each primer probe set was
individually optimized. Quantitative real-time PCR reactions were carried out in a total reaction
volume of 25 μl of iQ Supermix (BioRad) using BioRad iCycler iQ5. Transcript levels were
normalized to dGAPDH2. The primer/probe set for genes purchased from Applied Biosystems
were as follows: Hrb27C--Dm01803323_g1, xl6--Dm01803314_m1, TBPH--
Dm01820181_g1 and GAPDH2 ctl.-- Dm01843776_S1.
Cytotoxicity assays
To assess toxicity in HEK293T cells, cells were harvested at the indicated times with versene,
rinsed with PBS, and resuspended in PBS + 1% FBS. TOPRO-3 (Molecular Probes) in 1 mM
DMSO was diluted 1:50000 in PBS and 50 μL was added to 450μL of the cell suspension.
After incubation for 1-2 min, cells were analyzed by FACS. Transfected cells were identified
by DsRed fluorescence and dead cells were identified by TOPRO-3 fluorescence. Cell viability
was calculated and expressed as previously described (Taylor et al., 2003). To assess toxicity
in primary cortical neurons, we transfected these cells on day 4 in vitro with DsRed-conjugated
WT or mutant VCP. Twenty-four or 48 hours post-transfection, neurons were immunostained
for MAP2 and stained with DAPI to visualize nuclear morphology as described above. A
blinded investigator scored VCP-expressing neurons for the presence or absence of toxicity.
Only neurons with both condensed nuclei and loss of MAP2 staining were scored positive for
cytotoxicity. More than100 neurons from at least 3 trials were analyzed and results were
compared by using the Student t-test with a significance threshold of p<0.05).
Transcription assays
HEK293T cells were transfected with firefly luciferase reporter constructs (pLTR, pSP10 or
pSP10D) combined with 100ng pRL-CMV and 0.5ug VCP WT, VCP R155H, VCP A232E or
empty vector control (pcDNA 3.1) by using Fugene (Roche) according to the manufacturer’s
protocol. Forty-eight hours after transfection, cell lysates were analyzed using the Stop and
Glo dual reporter system (Promega) in a 96-well format with a Vector3 luminometer, as
directed by the Promega protocol. Firefly luciferase activity was then normalized to the Renilla
luciferase activity to control for transfection efficiency. Data was then normalized to activity
in cells transfected with empty vector control, which was given a value of 1.
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Histology
For immunofluorescence analysis in cell culture, HEK293T and HeLa cells were washed twice
with PBS, fixed with 4% PFA for 10 minutes, washed twice with PBS, then permeabilized
with 0.2% Triton X-100 in PBS for 10 minutes and blocked with 0.2% Triton/5% goat serum
in PBS for 30 minutes. Cells were incubated with primary antibody (rabbit polyclonal anti-
TDP-43 antibody at 1:200 and mouse monoclonal anti-MAP2 at 1:500, diluted in PBS
containing 0.2% Triton/5% goat serum) for 1.5 hour and washed twice with PBS (15 minutes
each). After the final wash, the cells were incubated with secondary antibody (diluted in PBS
containing 0.2% Triton/5% goat serum) for 1 hour, washed three times with PBS (5 minutes
each), and mounted with Vectashield + DAPI (Vector Laboratories Inc). Digital imaging was
performed with a Leica DMIRE2 fluorescent microscope using IP-LAB or Slidebook 5.1
software. To quantify fluorescence, regions of interest were drawn around the nuclei or
cytoplasm of transfected (DsRed-positive) cells or untransfected neighboring cells and the
intensity of FITC fluorescence emission from >100 cells was measured in at least three
experiments. For immunofluorescence analysis in Drosophila salivary glands, at least 5 third
instar wandering larvae expressing dVCP (WT or mutant) and TDP-43 (WT or mutant) under
control of the driver fkh-GAL4 were collected. Salivary glands from these larvae were
dissected in PBS and fixed in 4% PFA and heptane at room temperature. After 20 minutes, the
PFA was removed and 100% methanol added. After vigorous shaking for 1 minute the heptane
was removed and the samples washed in methanol 3 times. After 3 washes in PBST (PBS/
0.1% Tween-20) and 3 washes in PBSBT (PBS/0.1% Tween-20/1% BSA) the samples were
blocked for 2 hours in PBSBT at room temperature. Samples were incubated with primary
antibody (rabbit polyclonal anti-TDP-43 antibody at 1:300, diluted in PBSBT) overnight and
washed 4 times with PBSBT (30 minutes each). After the final wash, the cells were incubated
with secondary antibody (diluted in PBSBT) for 2 hours, washed three times with PBSBT (10
minutes each), and mounted with ProLong Gold antifade reagent with DAPI (Invitrogen).
Digital imaging was performed with a Leica DMIRE2 fluorescent microscope using Slidebook
software. All cells from the glands were evaluated for the absence of nuclear TDP-43 staining.
Using Slidebook software, DAPI was pseudo-colored in red.
For immunohistochemistry of fly eyes, heads of the appropriate genotype were collected and
fixed in 4% buffered paraformaldehyde in PBS for 2 hours at room temperature. Samples were
serially dehydrated in ethanol (1 h each in 50%, 70%, 80%, 90%, 95%, and twice in 100%).
Samples were then either: (1) embedded in JB-4 according to the manufacturer’s protocol (JB-4
Plus Embedding Kit, Polysciences, Inc.) and sectioned at 1 micron for staining with
Richardson’s or toluidine blue stains, or (2) embedded into paraffin, sectioned at 5 microns,
and placed on glass slides. Immunohistochemistry was performed using (ProteinTech) rabbit
anti-TDP43 at 1:200, Vector Rabbit HRP ImmPress detection, and Vector AEC substrate.
RESULTS
Exogenous expression of disease-related VCP mutants causes toxicity in a novel Drosophila
melanogaster model
To develop an in vivo model of VCP-mediated degeneration, we used Drosophila
melanogaster, in which the gene TER94 encodes the highly conserved orthologue of VCP. The
Drosophila VCP orthologue, hereafter referred to as dVCP, is 92% similar and 83% identical
to human VCP at the amino acid level. Conservation is even higher (95% similar, 84%
identical) across the 250–amino acid N-terminus, which hosts most known disease-causing
mutations, and all amino acid residues altered in disease are perfectly conserved. We introduced
R152H and A229E mutations into dVCP to create homologs of the R155H and A232E
mutations, which cause the most common and most severe forms of IBMPFD, respectively,
and generated transgenic flies. When these mutants were expressed in the fly eye or brain using
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the UAS/GAL4 system (Brand and Perrimon, 1993) we observed mutation-dependent
degenerative phenotypes despite equivalent levels of dVCP expression (Fig 1, Supplemental
Fig 1). In the eye, expression of WT dVCP caused a very modest phenotypic change, whereas
matched expression of the R152H and A229E mutants caused severe external rough eye
phenotypes with necrotic patches and histologically evident marked vacuolar degeneration.
The more severe phenotype seen in flies expressing the A229E mutant is consistent with the
more severe disease in patients with the A232E mutation.
When expressed broadly in the central nervous system, mutant dVCP reduced viability by
diminishing eclosion rates (Supplemental Fig. 1A), and surviving male flies had a significantly
reduced lifespan indicative of neurodegeneration (Supplemental Fig. 1B-C). Thus, this fly
model recapitulates the degeneration associated with disease-causing mutations in VCP in
tissue known to be affected (brain) and in a non-essential tissue (eye), which allows screening
to identify modifying genes.
A dominant modifier screen identifies RNA-binding proteins, including TBPH, as modifiers
of mutant-dVCP toxicity
VCP participates in a range of cellular activities and thus in diverse biological pathways. The
specific pathways underlying pathogenesis of IBMPFD, however, are unknown. As an
unbiased approach to identify molecules and pathways involved in mutant VCP–mediated
degeneration, we performed a dominant-modifier screen, using the moderate dVCP mutant
phenotype of dVCP R152H to maximize the likelihood of visualizing enhancement or
suppression of the mutant dVCP phenotype. To carry out the screen, we obtained a deficiency
(Df) collection representing all four chromosomes from the Bloomington Drosophila Stock
Center in order to scan the maximum proportion of genome (~80%) with the smallest number
of lines. From the primary screen, seventy-four deficiencies were identified as dominant
modifiers (enhancers or suppressors) of the dVCP R152H eye phenotype. After the secondary
screen, validation studies and individual gene interrogation by double-strand RNAi lines, we
identified three related genes: TBPH (CG10327), xl6 (CG10203) and Hrb27C (CG10377) that
dominantly suppress the degenerative phenotype (Figure 2A-B). RNAi-mediated knockdown
of these genes in the eye did not result in a phenotypic change independent of mutant dVCP
expression (Supplementary Figure 2A-D). However, in flies expressing dVCP R152H,
knockdown of these genes suppressed mutation-dependent degeneration (Figure 2B).
Suppression of degeneration in VCP-mutant flies was corroborated by seeing a significant
reduction in the blinded phenotypic severity score (Figure 2C) and by using additional RNAi
lines and classical alleles (Supplementary Figure 2E-F). We also generated transgenic lines
over-expressing TBPH, which resulted in a degenerative phenotype evident externally and
histologically when targeted to the eye. When exogenous TBPH was co-expressed with dVCP
R152H, degeneration associated with mutant VCP was enhanced, confirming the genetic
interaction (Fig 2D). Hrb27C, xl6 and TBPH correspond to the human genes DAZAP1, 9G8
and TDP-43, respectively. These are all RNA recognition motif (RRM)-containing RNA-
binding proteins that shuttle between the nucleus and cytoplasm (Huang and Steitz, 2001; Lin
and Yen, 2006; Ayala et al., 2008). Furthermore, all three have been shown to regulate multiple
aspects of RNA metabolism, including transcription, export, splicing and translation (Elvira
et al., 2006b; Swartz et al., 2007; Yang et al., 2009). We focused on TDP-43 for further
assessment, because cytoplasmic deposition of this protein is a prominent feature of IBMPFD
and other degenerative diseases (Geser et al., 2009).
Disease-related mutations in VCP cause cytotoxicity and lead to TDP-43 redistribution
In the brain, TDP-43 is found predominantly in the nuclei of neurons and some glial cells (Fig.
3A), although dynamic studies in vitro have shown TDP-43 to shuttle between the nucleus and
cytoplasm (Ayala et al., 2008). In IBMPFD, affected brain regions show gross abnormalities
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in TDP-43 localization, including clearance of TDP-43 from many nuclei and accumulation
in the cytoplasm; some neurons show dense nuclear inclusions of TDP-43 (Fig. 3B). To
examine the subcellular localization of TDP-43 in vitro, we first investigated whether VCP
mutation-dependent toxicity could be recapitulated in primary mouse cortical neurons
transfected with FLAG-conjugated WT VCP or mutant VCP (R155H and A232E). At 24 or
48 hours post-transfection, a blinded examiner scored VCP-positive neurons for changes in
MAP2 staining and nuclear morphology (changes in DAPI staining) to assess cytotoxicity
(Figure 3C). Quantitative analysis of the data revealed significant mutation-dependent toxicity
in primary neurons 48 hours post-transfection (Figure 3D). This time-dependent cytotoxicity
caused by mutant VCP was also demonstrated by fluorescence-activated cell sorting for living
vs. dead HEK293T cells. Exogenous expression of mutant but not WT VCP caused cell death
despite equivalent levels of VCP expression (Supplemental Fig. 3A-B).
To examine TDP-43 subcellular localization, we fixed and immunostained primary mouse
cortical neurons twenty-four hours post-transfection, before occurrence of the changes in
MAP2 staining or nuclear morphology. In neurons expressing FLAG vector alone or FLAG-
conjugated WT VCP, TDP-43 was consistently nuclear. By contrast, in cells transfected with
mutant VCP, we observed significant clearance of endogenous TDP-43 from nuclei and
accumulation in the cytoplasm (Fig. 3E-G). Redistribution of endogenous TDP-43 to the
cytoplasm was also observed in HEK293T cells expressing mutant but not wild type VCP
(Supplemental Fig. 3C-D). Exogenous expression of TDP-43 increased the amount of
cytoplasmic redistribution (Supplemental Fig. 3E-F). The nuclear depletion of TDP-43 in
primary neurons and HEK293T cells was corroborated by an associated loss of TDP-43’s
known nuclear function as a transcriptional repressor of testis-specific SP-10 gene (Acharya
et al., 2006). TDP-43 has been shown to interact with the SP-10 insulator, which prevents
luciferase expression by repressing the interaction between the CMV enhancer and SP-10 core
promoter in the pSP-10 construct (Fig. 3H). Mutation of the two TDP-43 binding sites
(ACACAC to GGGTTG) compromises the enhancer-blocking ability of the SP-10 insulator,
allowing luciferase expression (Fig. 3H). HEK293T cells were transfected with pSP10 or
pSP10-mutant luciferase reporter constructs and luciferase expression was quantified forty-
eight hours post-transfection as an indicator of TDP-43 nuclear function. When TDP-43
binding to SP10 was disrupted by use of the pSP10-mutant or by siRNA knockdown of TDP-43,
the normal repression of luciferase expression was attenuated. When mutant VCP, but not WT
VCP, was co-transfected with pSP10, the repression was released, allowing a significant
increase in luciferase expression. Cells co-transfected with VCP constructs and mutant pSP10
did not show greater luciferase activity than cells transfected with pSP10-mutant alone. Similar
results were found using the HIV-1 luciferase reporter plasmid (pLTR) (Supplemental Fig.
3G), a construct previously shown to rely on TDP-43 as a transcriptional repressor (Ou et al.,
1995). Thus, mutation-dependent VCP toxicity in primary neurons and HEK293T cells was
coincident with TDP-43 redistribution from the nucleus to the cytoplasm, as was also recently
observed in immortalized SH-SY5Y and U20S cells (Gitcho et al., 2009; Ju et al., 2009).
TDP-43 redistribution is also a conspicuous feature of numerous TDP-43 proteinopathies.
However, these observations do not tell us whether TDP-43 redistribution represents an
adaptive response to neuronal injury or, alternatively whether change in subcellular localization
mediates disease. Furthermore, if TDP-43 redistribution mediates disease, it leaves unclear
whether the mechanism involves loss of nuclear function or toxic gain of cytoplasmic function.
Mis-localization of TDP-43 to the cytoplasm causes degeneration
To further investigate the potential role of TDP-43 mislocalization in mutant–VCP-associated
degeneration in vivo, we generated multiple transgenic flies expressing human WT or mutant
TDP-43, using the UAS/GAL4 system. To target TDP-43 specifically to the nucleus or the
cytoplasm, we used TDP-43 with previously characterized mutations that disrupt the nuclear
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export sequence (NES) or the nuclear localization sequence (NLS)(Winton et al., 2008). Five
independent transgenic lines expressing WT TDP-43 in the fly eye showed a modest
degenerative phenotype (Figure 4 and Supplemental Fig 4A-B and 6A). A normal eye
phenotype was observed in 5 independent transgenic lines expressing NES-mutant TDP-43
(Fig 4 and Supplemental Fig 4C-D and 6A). By contrast, expression of NLS-mutant TDP-43
in the fly eye in 6 independent lines resulted in a strong degenerative phenotype and high-
molecular-weight smears of TDP-43 in immunoblots (Supplemental Fig. 5A-B and 6).
Immunostaining of NLS-mutant TDP-43 confirmed predominantly cytoplasmic localization,
while WT and NES-mutant TDP-43 remained predominantly nuclear (Fig. 4). To confirm that
the degenerative phenotype was caused by cytoplasmic localization of TDP-43 rather than
another effect of the NLS mutation, we also generated lines with truncated TDP-43 (80-414).
Deletion of the first seventy-nine amino acids, which disrupts the NLS, led to cytoplasmic
localization of TDP-43 and a degenerative phenotype indistinguishable from that observed
with NLS-mutant TDP-43 (Supplemental Fig. 5C and data not shown). These findings indicate
that accumulation of TDP-43 in the cytoplasm is sufficient to cause degeneration. Together
with the observation that knockdown of TBPH in flies causes no phenotypic change alone but
suppresses the mutant dVCP phenotype, these results indicate that a toxic gain of cytoplasmic
TDP-43 function underlies pathogenesis. However, these observations do not preclude the
possibility that a loss of TDP-43 nuclear function contributes to toxicity.
An ALS-causing mutation expressed in vivo leads to toxicity associated with cytoplasmic
redistribution of TDP-43
Missense mutations in TDP-43 have recently been identified in association with dominantly
inherited and sporadic ALS. To assess the effect of mutant TDP-43 in vivo, we generated
transgenic lines expressing TDP-43 with the ALS-causing mutation M337V (Sreedharan et
al., 2008). In 6 independent lines evaluated, we observed degenerative phenotypes ranging
from modest to severe (Fig 5A and Supplemental Fig 6A). The severity of the phenotype
correlated with the amount of abnormal TDP-43 species, including a C-terminal 25-kDa
fragment and high molecular weight bands (Fig 5 and Supplemental Fig 6B). This is similar
to the pathogenic biochemical signature seen in patient tissue with TDP-43 proteinopathy
(Neumann et al., 2007). Immunohistochemistry for TDP-43 in these eyes showed a marked
cytoplasmic distribution of TDP-43, consistent with a recent report that this mutation increases
cytoplasmic TDP-43 inclusions in vitro (Nonaka et al., 2009).
Mutation-dependent genetic interaction of dVCP and TDP-43 is associated with cytoplasmic
redistribution of TDP-43 in vivo
To assess the relationship between dVCP and TDP-43 in vivo, we performed an epistasis study
by co-expressing dVCP (WT or mutant) with TDP-43 (WT or mutant) and analyzing changes
to external eye phenotype by light microscopy (Fig 6A) and in subcellular localization of
TDP-43 by immunohistochemistry (Fig 6B). Crosses with most of our NLS-mutant TDP-43
lines resulted in lethality; we therefore used line #5 that exhibits a very mild phenotype (all
lines are shown in Supplemental Fig. 5A). Due to the severe degradative loss of internal eye
tissue in some genotypes, immunohistochemistry of TDP-43 in the eye (Fig 6B) was
corroborated with quantitative immunofluorescence analysis of TDP-43’s subcellular
distribution in larval salivary glands (Fig 6C-D).
This epistasis study indicated no interaction between WT dVCP and WT or NES-mutant
TDP-43 (Fig. 6A, C). However the combination of WT dVCP with a weak NLS-mutant resulted
in mild enhancement of the pathologic phenotype. The combination of WT dVCP with a strong
NLS-mutant TDP-43 resulted in lethality. Notably, the subcellular distribution of WT and
mutant TDP-43 was not altered by co-expression with WT dVCP (Fig. 6B-D). By contrast, the
degenerative phenotype of mutant dVCP-R152H was strongly enhanced by co-expression of
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WT TDP-43 (Fig. 6A, C), and this result was associated with significant clearance of WT
TDP-43 from nuclei and accumulation in cytoplasm (Fig. 6B-D). Importantly, the dVCP-
R152H phenotype was not enhanced by co-expression with NES-mutant TDP-43 (Fig. 6A, C),
and the subcellular distribution of NES-mutant TDP-43 remained nuclear (Fig. 6B-D).
Unsurprisingly, the dVCP-R152H phenotype was enhanced by NLS-mutant TDP-43 (Fig. 6A,
C), and NLS-mutant TDP-43 was found predominantly in the cytoplasm (Fig. 6B-D). When
the ALS-associated mutation TDP-43 M337V was co-expressed with WT dVCP, the
phenotype was enhanced, and lethality resulted when the M337V mutant was co-expressed
with mutant dVCP (Fig. 6A, C). Thus, genetic interaction between dVCP and WT TDP-43
was dependent on a disease-causing mutation in dVCP and was associated with redistribution
of TDP-43 from the nucleus to the cytoplasm. TDP-43 restricted to the nucleus failed to interact
with mutant VCP. The interaction of VCP with a known ALS-causing TDP-43 mutant further
underscores the importance of cytoplasmic TDP-43 in VCP mutation-dependent degeneration.
DISCUSSION
We have developed and characterized a highly tractable Drosophila model of IBMPFD that
exhibits VCP mutation-dependent degeneration (Fig.1 and Supplemental Fig. 1). Using this
model we identified multiple, related RNA-binding proteins that genetically modified
degeneration and one of these was TBPH, the Drosophila orthologue of TDP-43. We further
demonstrated that VCP and TDP-43 interacted genetically, that disease-causing mutations in
VCP led to redistribution of TDP-43 to the cytoplasm in vitro and in vivo, and that this
redistribution was sufficient to cause degeneration in vivo. We also determined that a
pathogenic mutation in TDP-43 enhanced the genetic interaction with VCP. Taken together,
our results show that toxic gain-of-function of TDP-43 in the cytoplasm contributes to
degeneration initiated by mutations in VCP.
TDP-43 pathology is a prominent pathological feature in a broad array of sporadic and inherited
human diseases including ALS, FTD-TDP, Perry Syndrome and IBMPFD (Neumann et al.,
2007; Geser et al., 2009; Salajegheh et al., 2009). In these diseases, TDP-43 is found to be
redistributed from the nucleus to the cytoplasm in affected neurons, although the significance
of this has been unclear. In brain and muscle of IBMPFD patients, TDP-43 redistributes to the
cytoplasm where it co-localizes with ubiquitin-immunopositivity, and is also present in
lenticular nuclear inclusions (Guinto et al., 2007). Expression of mutant VCP in SH-SY5Y
cells (Gitcho et al., 2009), U20S cells (Ju et al., 2009) and in primary neurons (Fig 3) resulted
in redistribution of TDP-43 to the cytoplasm, although no nuclear inclusions were observed.
TDP-43 also redistributes to the cytoplasm in response to neuronal injury where it co-localizes
with stress granules (Colombrita et al., 2009; Moisse et al., 2009a). Therefore, it was unclear
whether the redistribution of TDP-43 in the setting of mutant VCP-related disease was a
mediator of pathogenesis or an indicator of cytotoxic stress caused by disease. The results
presented here clarify this issue, indicating that TDP-43 is a mediator of toxicity initiated by
disease-causing mutations in VCP. This is illustrated by suppression of degeneration in the
IBMPFD model when endogenous TBPH is depleted (Fig 2B, C) and enhancement of
degeneration when TBPH or TDP-43 is over-expressed (Figs 2D and 6). While our results
indicate that accumulation of TDP-43 in the cytoplasm contributes to cytotoxicity, they do not
exclude the possibility that depletion of nuclear TDP-43 also contributes to cytotoxicity.
The mechanism by which mutations in VCP influence the subcellular distribution of TDP-43
is unknown, but we outline several possibilities here (Figure 7). First, the nuclear depletion
and cytoplasmic accumulation of TDP-43 might reflect a defect in the well-established role of
VCP in ubiquitin-dependent segregation of substrates from multiprotein complexes. It is
known that TDP-43 is present in the cytoplasm at low levels normally, where it is found in
ribonucleoprotein complexes implicated in translation regulation (Freibaum et al.; Elvira et al.,
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2006a;Wang et al., 2008;Moisse et al., 2009b). Perhaps VCP activity is necessary for removal
of TDP-43 from ribonucleoprotein complexes to permit recycling and impairment of this
activity by disease-causing mutations leads to progressive accumulation of TDP-43 in the
cytoplasm. A second possibility is that VCP directly participates in nuclear import of TDP-43.
VCP was previously shown to regulate the nuclear import of the TSAd protein (T cell-specific
adaptor protein) in T cell signal transduction (Marti and King, 2005). This aspect of VCP
function may involve the adaptor Npl4 (nuclear protein localization-4), originally discovered
in a yeast screen for mutants deficient in nuclear protein import (DeHoratius and Silver, 1996)
(Fabre and Hurt, 1997). Perhaps VCP regulates nucleocytoplasmic shuttling of additional
proteins, including TDP-43, and that disease mutations impair this activity. A third possibility
relates to the recently discovered role of VCP in autophagy, and the finding that disease-causing
mutations in VCP impair autophagy (Ju and Weihl; Tresse et al.). Since autophagy may be
important for turnover of cytoplasmic TDP-43 (Wang et al.), accumulation of TDP-43 in the
cytoplasm may simply reflect a defect in this degradation pathway. These three possibilities
are not mutually exclusive and it is also possible that redistribution of TDP-43 in IBMPFD
reflects defects in VCP functions that are presently unknown.
The present study shows that degeneration initiated by mutations in VCP is mediated in part
through toxic gain-of-function of TDP-43 in the cytoplasm. The basis for toxicity associated
with excess cytoplasmic TDP-43 is unclear, but this observation is consistent with the recent
report showing that (1) cytoplasmic mislocalization of TDP-43 is toxic to neurons and (2)
mutations in TDP-43 that cause familial ALS promote cytoplasmic mislocalization (Barmada
et al., 2010). There is some evidence to suggest that TDP-43, or a fragment of TDP-43, is
intrinsically prone to aggregation resulting in the formation of a toxic species (Johnson et al.,
2009; Zhang et al., 2009). Indeed, we have observed a correlation between TDP-43 toxicity
in vivo and the presence of TDP-43 cleavage products or high molecular weight species of
TDP-43 (Figure 5, Supplemental Figures 4-6), although this study does not address whether
there is a cause and effect relationship between these abnormal species and toxicity. Whether
or not TDP-43 aggregation promotes toxicity, we are particularly intrigued by the possibility
that excess cytoplasmic TDP-43 perturbs some aspect of cytoplasmic RNA metabolism. The
notion that a defect in RNA metabolism contributes to IBMPFD pathogenesis is supported in
the present study by the identification of xl6 (the Drosophila ortholog of human SR protein
9G8) and Hrb27C (the fly ortholog of the human hnRNP DAZAP1) as dominant modifiers of
mutant-VCP toxicity in vivo. This notion is further supported by the high frequency with which
inherited neurodegenerative diseases are caused by mutations that impair RNA metabolism,
either through mutations in RNA-binding proteins or through mutations in RNA that impair
the function of RNA binding proteins (La Spada and Taylor; Cooper et al., 2009). The extent
to which perturbation in RNA metabolism contributes to TDP-43 proteinopathies in general,
and IBMPFD in particular, will be fascinating to learn as the field moves forward.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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